abrogated acute and cumulative mortality with improvement in long-term survival (n = 10, P < 0.05; Figures 1a and b) . Thus, use of a potassium channel opener imparts enhanced protection, identifying pharmacological targeting of K ATP channel function as a novel strategy for prevention of death in cocaine overdose.
Cocaine-induced mortality is a leading cause of deaths ascribed to drug abuse; yet, limited information is presently available regarding the identity of the genetic determinants defining prognosis. The present study, using the Kir6.2-KO model, provides first evidence linking the status of K ATP channels with outcome in cocaine abuse, establishing in vivo a novel susceptibility mechanism in cocaine toxicity. K ATP channels are uniquely positioned to serve as stress-responsive elements as they harness the capacity to translate signals of cellular distress into protective stress adaptation. 11, 12 While the intimate events underlying the beneficial role of K ATP channels in cocaine intoxication remain to be established, K ATP channel activation provides a feedback control necessary for preservation of cellular homeostasis under stress by regulating action potential duration and thus Ca 2 þ influx, preventing the deleterious consequences of Ca 2 þ overload associated with hyperadrenergic states. 5, 12 While the hyperadrenergic effect of cocaine sets the conditions for K ATP channel opening, a direct inhibitory effect of cocaine could result in suboptimal activation of the channel. 13 In fact, use of K ATP channel opening drugs, known to reduce intracellular Ca 2 þ loading, 10 were discovered here as effective in abrogating the lethal effect of cocaine overdose, opening a new therapeutic avenue in managing substance abuse.
The present demonstration that K ATP channels protect against cocaine-induced death provides a foundation for translational investigation of the role of these cytoprotective channels in the population exposed to cocaine use. Recognition of individuals with a genetic background predisposing to increased risk, and further evaluation of the effectiveness of K ATP channel-based therapeutic strategies will provide a critical step towards a personalized approach to prevention and management of life-threatening consequences of cocaine overdose. Recently, Wong et al. 1 investigated an association between polymorphisms in phosphodiesterase (PDE) genes and antidepressant response in a MexicanAmerican population. Two single nucleotide polymorphisms (SNPs) were associated with remission in response to either fluoxetine or desipramine although sample sizes for remitter and nonremitter groups were of limited size. Association between the reported PDE gene SNPs and remission in response to antidepressants requires further investigation using larger sample sizes. We sought to replicate the response phenotype data for two SNPs, rs1549870 (PDE1A) and rs1880916 (PDE11A) in a similar ethnic group for the nonremitter vs remitter analysis in the Wong et al.
study. Additionally, we examined this potential association in Non-Hispanic Caucasians and AfricanAmerican samples.
Our sample was derived from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a large-scale prospective clinical trial involving 4041 adults with nonpsychotic major depressive disorder (MDD). Details regarding the STAR*D study have been extensively described elsewhere. 2, 3 Briefly, severity of depression was assessed with the 16-item Quick Inventory of Depressive Symptomatology Self Report before and during up to 12 weeks of treatment with the selective serotonin reuptake inhibitor, citalopram. DNA from 1953 subjects were obtained from the STAR*D study. We used 1804 subjects undergoing X42 days of citalopram treatment, and classified individuals as responders if they had a final Quick Inventory of Depressive Symptomatology Self Report score 50% reduced from baseline score. Remitters were defined as those with a final Quick Inventory of Depressive Symptomatology Self Report score p5. 4 We had 110 responders (87 remitters and 23 nonremitting responders) and 94 nonresponders among our 204 Hispanic Caucasians. We extended the Wong et al. findings to NonHispanic Caucasians, for which we had 689 responders (592 remitters and 97 nonremitting responders) and 417 nonresponders; and African Americans, for which we had 130 responders (100 remitters and 30 nonremitting responders) and 121 nonresponders. Genotypes of subjects were determined using 5 0 nuclease (TaqMan) assays and an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using the manufacturer's recommended protocol. An unconditional logistic regression was used to examine associations between the two selected SNPs and (1) nonremitters vs remitters and (2) nonresponders vs responders in Hispanic-Caucasian, Non-Hispanic-Caucasian and African-American groups. Because we were attempting to replicate the Wong et al. findings, we used a significance threshold of 0.05. Both SNPs were found to be in Hardy-Weinberg equilibrium (Table 1) . No significant association between rs1880916 or rs1549870 with HispanicCaucasian citalopram remitters was observed when compared to nonremitters (P = 0.16 and 0.41, respectively). This result contrasts with findings by Wong et al. in which rs1880916 and rs1549870 were found to be associated (P = 0.04 and 0.005, respectively) with response to fluoxetine (a selective serotonin reuptake inhibitor) or desipramine in Mexican Americans in a sample of 82 remitters and 61 nonremitters. Furthermore, odds ratios for these associations differ in magnitude and directionality between the two studies. With comparable sample sizes, our analysis of Hispanic-Caucasian remitters and nonremitters should provide sufficient power to replicate the initial finding. Nevertheless, the findings in this group should still be considered provisional without further replication. No association was seen using a broader comparison of responders to nonresponders (P = 0.58 and 0.40, respectively). No association for rs1880916 and rs1549870 with citalopram response (P = 0.48 and 0.71, respectively) or remission (P = 0.60 and 0.19, respectively) was observed in Non-Hispanic Caucasians. Finally, in African-American subjects, no significant association for these SNPs with remission (P = 0.21 and 0.89, respectively) or for rs1549870 with response (P = 0.64) was detected. A nominal association between rs1880916 and response (P = 0.02) was detected in our African-American group but this finding requires replication in a larger sample.
There are several potential reasons for the discrepancies between our work and that of Wong et al. The difference in treatments between the studies (fluoxetine or desipramine vs citalopram) or assessment measures/thresholds or depression severity/chronicity/refractoriness may make direct comparison difficult. Wong et al. used subjects with three Mexican grandparents, while our sample was defined by selfreport of Hispanic ethnicity. Nevertheless, the marker allele frequencies are similar between the studies. For example, rs1549870 had a minor allele frequency of MTHFR is an enzyme involved in the metabolism of folic acid, by catalysing the reduction of 5,10-methylenetetrahydrofolate to 5-methyl tetrahydrofolate. This reaction acts as a methyl donor in the conversion of homocysteine, a product formed during methylation reactions, to methionine. Methionine is a precursor for S-adenosyl methionine, an important enzyme in the catabolism of methylation reactions in the central nervous system. Impairment in the conversion of homocysteine into methionine results in an increase in homocysteine levels, which can be deleterious through the inhibition of methylation reactions if left to accumulate. 1 There is a common C677T functional variant in the MTHFR gene resulting in an amino-acid transition from alanine to valine. This change leads to a thermolabile version of MTHFR with reduced enzymatic activity. 4 There are a number of studies that suggest an association between the low-activity allele (677T) and major depression, however there are also a number of negative reports. 1 Recently, Lewis et al.
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performed an association in a large female population sample and found an association between the MTHFR 677T allele and an increase in self-reported depression symptoms. To complement their analysis, they performed a meta-analysis on all previous reports, finding a combined odds ratio of 1.36 for the 677T allele in depression, thus indicating that this genetic variant is a small but significant risk factor for depression. For this study, C677T (rs1801133) was genotyped in 583 nuclear families ascertained through a child or adolescent with a diagnostic and statistical manual of mental disorders IV diagnosis of a mood disorder (unipolar or bipolar) before 15 years of age (childhood-onset mood disorder). Families consisted of 717 affected children (583 probands and 134 affected siblings). The recruitment and assessment of this sample has been described previously. 6 Genotyping was performed using the TaqMan 5 0 nuclease assay (Applied Biosystems, Foster City, CA, USA) (ABI probe ID, C_1202883_20). Transmission disequilibrium test analysis was performed using TDT phase. 7 Power calculations were permutated by the Quanto program (http://hydra.usc.edu/gxe). The minor allele frequency for this marker was 0.35 in this sample, which is consistent with previous studies and no deviation from the Hardy-Weinberg equilibrium was observed.
